Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | USP8 | P40818 | 1/20 | 0.32 |
| ▸ | USP5 | P45974 | 1/20 | 0.32 |
| ▸ | USP4 | Q13107 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736484 | 0.77 | ALDH1A1 (0.34) | CYP19A1KDM4EALDH1A1L3MBTL1HPGD | |
| SCHEMBL13617004 | 0.77 | CNR2 (0.43) | KDM4EUSP2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL25594828 | 0.73 | CYP19A1 (0.36) | CYP19A1KDM4EUSP2ALDH1A1MAPT | |
| SCHEMBL16707477 | 0.71 | USP2 (0.44) | USP2ALDH1A1MAPTHTTUSP8 | |
| SCHEMBL19197220 | 0.69 | BRD4 (0.42) | CYP19A1KDM4EALDH1A1MAPTHTT | |
| SCHEMBL16707519 | 0.69 | USP2 (0.39) | USP2ALDH1A1MAPTHTTUSP8 | |
| SCHEMBL16707476 | 0.68 | USP2 (0.41) | USP2ALDH1A1MAPTHTTUSP8 | |
| SCHEMBL25595252 | 0.65 | CTSK (0.33) | CYP19A1KDM4EUSP2ALDH1A1USP8 | |
| SCHEMBL2736479 | 0.65 | DAO (0.46) | KDM4EUSP2ALDH1A1MAPTMEN1 | |
| SCHEMBL15975183 | 0.65 | GRIA1 (0.36) | CYP19A1KDM4EALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | CNR2, CNR1, NPY2R | CYP19A1 793/4885KDM4E 1679/4885USP2 3543/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | CYP19A1 3011/4885KDM4E 3245/4885USP2 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.